Intratumoural oncolytic HSV-1 reshapes the local and systemic immune landscape through CD8 ⁺ T cell reprogramming
Preprint
Abstract
Most oncolytic viruses are delivered by intratumoural injection, and local administration can induce regression of both injected and distant tumours in mice and patients. However, the mechanisms by which local viral infection reprograms systemic immunity remain poorly understood. Here we show that intratumoural RP1, an oncolytic HSV-1 encoding GM-CSF and GALV-GP-R ⁻ , drives regression of injected and uninjected murine melanoma tumours and prolongs survival. RP1 elicits coordinated CD4 ⁺ and CD8 ⁺ T cell infiltration accompanied by local cytokine remodelling, reshaping the immune landscape at both tumour sites. Leveraging the Timer of Cell Kinetics and Activity (Tocky) system and Kaede photoconvertible protein technology, we resolve the temporal dynamics of CD8 ⁺ T cell responses following local virotherapy and identify two systemically induced, virus-driven CD8 ⁺ T cell populations distinguished by TCR engagement kinetics: antigen-engaged Timer-positive ‘viral-induced precursors’ (VIPs) and Timer-negative KLRG1 ⁺ ‘viral-induced terminal effectors’ (VITEs). Single-cell transcriptomic and pseudotime analyses reveal divergent differentiation trajectories; VIPs exhibit sustained antigen engagement within the tumour microenvironment (TME), a transcriptional programme associated with self-renewal, and preferential homing to draining lymph nodes. A VIP-associated gene signature correlates with clinical response to RP1 plus PD-1 blockade in the IGNYTE trial of RP1 and nivolumab in PD-1-refractory melanoma and is independently associated with response to immune checkpoint inhibitor (ICI) therapy in melanoma. These findings establish a mechanistic link between local oncolytic virotherapy, systemic CD8 ⁺ T cell reprogramming, and durable regression of distant lesions in patients.Keywords
This publication has 31 references indexed in Scilit:
- Oncolytic viruses as anticancer agents: clinical progress and remaining challengesThe Lancet, 2025
- Protocol for transcutaneous tumor photolabeling to track immune cells in vivo using Kaede miceSTAR Protocols, 2024
- Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodesCell, 2023
- ‘Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responsesNature Immunology, 2022
- Defining ‘T cell exhaustion’Nature Reviews Immunology, 2019
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockadeNature Immunology, 2019
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- T Cell Dysfunction in CancerCancer Cell, 2018
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in MiceCancer Cell, 2009